Tilmanocept Dose - 0.20 mg for Diabetic Kidney Disease

UC San Diego Medical Center, San Diego, CA
Diabetic Kidney DiseaseTc-99m-Tilmanocept - DiagnosticTest
Eligibility
18+
All Sexes

Study Summary

This trial will use a SPECT/CT scan of the kidneys using Tc-99m-tilmanocept to look for changes in the kidneys of diabetics that could indicate different stages of kidney disease.

Eligible Conditions
  • Diabetic Kidney Disease

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Approximately 1 hour

Approximately 1 hour
Standard uptake value in the kidney

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

3 Treatment Groups

Tilmanocept Dose - 0.20 mg
1 of 3
Tilmanocept Dose - 0.050 mg
1 of 3
Tilmanocept Dose - 0.40 mg
1 of 3

Active Control

120 Total Participants · 3 Treatment Groups

Primary Treatment: Tilmanocept Dose - 0.20 mg · No Placebo Group · Phase 1

Tilmanocept Dose - 0.20 mg
DiagnosticTest
ActiveComparator Group · 1 Intervention: Tc-99m-Tilmanocept · Intervention Types: DiagnosticTest
Tilmanocept Dose - 0.050 mg
DiagnosticTest
ActiveComparator Group · 1 Intervention: Tc-99m-Tilmanocept · Intervention Types: DiagnosticTest
Tilmanocept Dose - 0.40 mg
DiagnosticTest
ActiveComparator Group · 1 Intervention: Tc-99m-Tilmanocept · Intervention Types: DiagnosticTest

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 1 hour

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,051 Previous Clinical Trials
1,827,287 Total Patients Enrolled
Carl Hoh, MDPrincipal InvestigatorUC San Diego Medical Center

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have the same medical condition as described in the group section above.

Frequently Asked Questions

How many individuals are participating in this medical investigation?

"Affirmative. The details provided on clinicaltrials.gov suggest that this medical trial, which was initially listed on August 6th 2021 is still actively recruiting patients for participation. Around 120 individuals must be enrolled from a single site." - Anonymous Online Contributor

Unverified Answer

Has the FDA verified the efficacy of Tilmanocept Dose - 0.40 mg?

"Tilmanocept Dose - 0.40 mg safety has only been partially evaluated, thus receiving a score of 1 on our scale from one to three." - Anonymous Online Contributor

Unverified Answer

Are there still spots available for participants in this experiment?

"Clinicaltrials.gov confirms that, as of 16th February 2022, this clinical trial is actively recruiting individuals to participate. The study first appeared on 6th August 2021." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.